This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While the market was worth over $6 billion in 2012, this has now grown to nearly $48 billion only a decade later, said Avigayil Chalk, PhD, GlobalData’s Senior Oncology and Haematology analyst, at an immuno-oncology webinar held on May 23. was powered by the advent of immune-checkpoint inhibitors, added Chalk.
Vaccines have been an essential part of protecting public health for decades. However, despite the overwhelming evidence for their effectiveness and safety, there has been an increasing trend of vaccine hesitancy in recent years. What is vaccine hesitancy? Are there any long-term risks with vaccines?
We also highlight our members' perspectives on immunizations, community healthcare providers and patient experience. She shared insight on topics including in-pharmacy pediatric vaccinations, immunization guidelines, receiving multiple vaccinations at one time, and new immunization opportunities on the horizon.
We also highlight our members' perspectives on health outcomes, oral oncolytics and vaccination recommendations. In a second session, he reviewed the latest updates on vaccines for meningococcal disease, human papillomavirus, and tetanus, diphtheria, and pertussis, among others. Learn more about the summit and PQA Convenes t below.
In the October 2021 edition of the American Journal for Managed Care, EQUIPP® was highlighted in an article on how a collaborative effort of MAPD plans with community pharmacies could impact vaccination rates for pneumonia and influenza by providing low site of care cost immunizations to the populations served. Sheer et al.,
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content